Encorafenib: Interim Phase Ib/II data

Interim data from 102 patients with advanced BRAF mutation-positive mCRC who failed >=1 prior therapy in an open-label, international Phase Ib/II trial showed that once-daily 200 mg oral encorafenib plus Erbitux cetuximab and alpelisib led to a median PFS of 5.4 months vs. 4.2 months for encorafenib plus Erbitux without alpelisib (HR=0.69, 95% CI: 0.43, 1.11, p=0.064). Encorafenib plus Erbitux and alpelisib led to a confirmed ORR of 27% vs. 22% for encorafenib plus Erbitux without alpelisib. Median OS was 15.2 months for the triplet combination vs. not yet reached for the doublet combination. The MTD was not determined for either combination. The most common grade 3/4 adverse events reported were anemia, hyperglycemia, and elevated lipase levels. Data will be presented at the American Society of Clinical Oncology meeting in Chicago. ...